Company attributes
Other attributes
Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.
Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.
- Sequencing patient's tumor
- Mapping of mutations
- Bioinformatic algorithms
- Selection of neoepitopes
BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.
